The Biospecimen Repository Core is designed to provide support to the basic translational research efforts ofthe SPORE. The Core will play a central role in collecting, annotating, storing, distributing, and tracking prostate cancer tissue and blood biospecimens from patients enrolled in research protocols. Detailed biospecimen annotation, including documentation of preanalytic processing variables, pathology findings, and patient clinical history information will be recorded in robust relational databases. We will conduct rigorous data quality assurance and quality control measures, and standardized longitudinal follow-up of all consented patients with materials in the prostate biospecimen repository. The Core will provide SPORE investigators with expert histopathological evaluation of tumor samples both from patients enrolled on research protocols and from xenograft models. The Core will also provide assistance in performing and interpreting immunohistochemical and in situ hybridization assays, in selecting tissue for microdissection and construction of arrays, and in collaborating with project leaders and the Biostatistics Core.
Specific Aim 1. To maintain and expand a model prostate cancer resource to collect, annotate, store, and distribute biospecimens for translational prostate cancer research.
Specific Aim 2. To perform systematic pathologic evaluation of all human and animal tissue samples and preparation of appropriate tissues for use by SPORE investigators. Furthermore, the Core aims will serve as a focal point to help combine and prioritize a variety of institutional pathology systems-related development efforts, and we plan to document and publish our findings, standard operating procedures, and best practices, to better serve the research community. Core A will serve RP-2, Core D.

Public Health Relevance

Through the work of this SPORE, supported by the Biospecimen Repository Core, we hope to increase our understanding of the clinical, biologic, and genetic basis of prostate cancer in an effort to improve patient outcome, to facilitate a range of scientific activities that could lead to new genomic- and proteomic-based interventions for cancer, including target identification and validation, and to develop new biomarkers, diagnostics, and pharmacogenomic analyses.

Agency
National Institute of Health (NIH)
Type
Specialized Center (P50)
Project #
5P50CA092629-14
Application #
8730091
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
14
Fiscal Year
2014
Total Cost
Indirect Cost
City
New York
State
NY
Country
United States
Zip Code
10065
Cheal, Sarah M; Punzalan, Blesida; Doran, Michael G et al. (2014) Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcino Eur J Nucl Med Mol Imaging 41:985-94
Bancroft, Elizabeth K; Page, Elizabeth C; Castro, Elena et al. (2014) Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur Urol 66:489-99
Sjoberg, Daniel D (2014) Toward a Smarter Prostate Cancer Screening Program. Eur Urol :
Ehdaie, Behfar; Vertosick, Emily; Spaliviero, Massimiliano et al. (2014) The impact of repeat biopsies on infectious complications in men with prostate cancer on active surveillance. J Urol 191:660-4
Ahmad-Tajudin, Asilah; Adler, Belinda; Ekstrom, Simon et al. (2014) MALDI-target integrated platform for affinity-captured protein digestion. Anal Chim Acta 807:1-8
Vickers, Andrew J (2014) Clinical trials in crisis: Four simple methodologic fixes. Clin Trials 11:615-21
Bryant, Richard J; Lilja, Hans (2014) Emerging PSA-based tests to improve screening. Urol Clin North Am 41:267-76
Vertosick, Emily A; Poon, Bing Ying; Vickers, Andrew J (2014) Relative value of race, family history and prostate specific antigen as indications for early initiation of prostate cancer screening. J Urol 192:724-8
Vickers, Andrew J; Pepe, Margaret (2014) Does the net reclassification improvement help us evaluate models and markers? Ann Intern Med 160:136-7
Shi, Yuji; Wang, Junru; Chandarlapaty, Sarat et al. (2014) PTEN is a protein tyrosine phosphatase for IRS1. Nat Struct Mol Biol 21:522-7

Showing the most recent 10 out of 310 publications